Henlius licenses Phase 3 innovative HER2 ADC from GeneQuantum

CAR-T Digest - August 2020

19 August 2025: Henlius licenses Phase 3 innovative HER2 ADC from GeneQuantum

Henlius has licensed exclusive development and commercialization rights for GeneQuantum’s HER2-targeted ADC GQ1005 in China and selected overseas markets, the drug is currently in Phase 3 trials for HER2-positive breast cancer
GQ1005, developed with GeneQuantum’s enzymatic site-specific conjugation technology, links a topoisomerase I inhibitor payload to an anti-HER2 antibody via a stable cleavable linker, enabling strong bystander effects with reduced systemic toxicity
Preclinical studies showed comparable efficacy to trastuzumab deruxtecan (T-DXd) but with a better safety profile, while Phase 1 data presented at AACR 2024 demonstrated favorable tolerability and early efficacy in breast, gastric, and lung cancers
Henlius aims to expand its comprehensive breast cancer portfolio, which already includes approved products like HANQUYOU (approved in 50+ countries, benefiting 260,000+ patients) and pipeline assets such as HLX11, HLX22, HLX78, and HLX97